Recent events
Recent events tied to this brand in public sources.
Back to profile76 entries · Page 1 of 4
2026
Merck raises adjusted profit outlook
Merck raised its adjusted earnings outlook to $2.77–$2.82 per share, from its previous range of $2.66–$2.76 per share.
2026
Merck opens bioprocessing production center in Daejeon
Merck opened its Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea, expanding its regional manufacturing capacity for materials and solutions used in biologic medicines.
2026
Merck officially opens 120,000-square-foot Advance research facility at West Point, Pennsylvania campus
Merck on Wednesday (Oct 14, 2026) officially opened its new 120,000-square-foot research facility, named Advance, on its West Point, Pennsylvania campus, with a ribbon-cutting ceremony attended by Pennsylvania Gov. Josh Shapiro and other officials. The facility features highly automated robotic systems and advanced digital AI capabilities. Speaking after the opening, Merck CEO Rob Davis told CNBC he expects the company's personalized cancer vaccine developed with Moderna to become faster to manufacture over time, while noting the current focus is ensuring supply and market readiness for the vaccine, which is paired with Keytruda.
2022
Unlearn and Merck KGaA announce multi-year collaboration
Unlearn announced a multi-year collaboration with Merck KGaA to accelerate late-stage clinical trials using trial designs that include Digital Twins. The collaboration will initially focus on advancing regulatory approval of candidates in Merck KGaA's immunology pipeline, with potential to expand to other therapeutic areas.
2022
Merck and Palantir partner on Athinia platform
Merck announced a partnership with Palantir Technologies to develop Athinia, a secure collaborative data analytics platform for the semiconductor industry.
2022
Merck KGaA exercises fourth licensing option in F-star collaboration
Merck KGaA exercised a fourth licensing option in its immuno-oncology collaboration with F-star Therapeutics.
2021
FDA authorizes Merck’s COVID-19 pill
The U.S. Food and Drug Administration authorized Merck’s molnupiravir for treatment of mild-to-moderate COVID-19 in adults at risk for severe disease when alternative treatments are not accessible or clinically appropriate.
2021
Merck to acquire Chord Therapeutics
The article reports that Chord Therapeutics is being acquired by Merck. The acquisition is intended to expand Merck's neurology pipeline and support development of Chord's lead drug candidate, CRD1.
2021
Merck announces investment in Taiwan
Merck announced plans to invest approximately NT$17 billion in Taiwan over the next five to seven years to expand electronic technology production lines and R&D capacity. The plan is expected to create about 400 jobs.
2021
Merck completes acquisition of Acceleron Pharma
Merck announced that it had successfully completed its acquisition of Acceleron Pharma Inc.
2021
Merck launches ColorWheel flow cytometry portfolio
Merck announced the launch of its ColorWheel flow cytometry portfolio, which allows users to select antibodies and dyes for assembly in desired combinations.
2021
Merck opens silica-based pigments production line in Germany
Merck KGaA opened a new production line for silica-based effect pigments at its Gernsheim, Germany manufacturing site. The company said the facility would increase production capacity for silicon dioxide flakes.
2021
Illumina and Merck announce HRD testing partnership
Illumina and Merck announced a partnership to develop and commercialize tests that identify genetic mutations used in assessing homologous recombination deficiency. Illumina will develop an HRD companion diagnostic test for the EU and UK and a research-use-only HRD assay for planned global availability excluding the United States and Japan.
2021
Merck funds COVID-19 research at IIT Bombay
Merck announced a donation of Rs 1.7 crore over two years to IIT Bombay to support development of clinical tests for assessing COVID-19 disease severity.
2021
FDA approves Welireg for von Hippel-Lindau disease-associated cancers
The FDA approved belzutifan (Welireg) for adults with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not require immediate surgery.
2021
Merck files Januvia patent suit against Laurus
Merck Sharp & Dohme Corp. filed a patent suit in the District of Delaware against Laurus Labs Limited and Laurus Generics Inc. after the defendants submitted an ANDA to the FDA seeking to produce a generic version of Januvia. Merck is seeking a declaration of patent infringement; the filing describes the alleged infringement, not a court determination.
2021
Merck launches AZ 910 resist remover
Merck announced the launch of AZ 910, a new resist remover for semiconductor chip manufacturing.
2021
FDA approves KEYTRUDA for high-risk early-stage triple-negative breast cancer
The U.S. Food and Drug Administration approved Merck's KEYTRUDA, in combination with chemotherapy before surgery and as a single agent after surgery, for patients with high-risk early-stage triple-negative breast cancer.
2021
FDA approves Keytruda–Lenvima combination for advanced endometrial carcinoma
The U.S. Food and Drug Administration approved Keytruda in combination with Lenvima for certain patients with advanced endometrial carcinoma following prior systemic therapy who are not candidates for curative surgery or radiation.
2021
FDA approves Merck's Vaxneuvance vaccine
The FDA approved Merck’s Vaxneuvance 15-valent pneumococcal conjugate vaccine for adults aged 18 years or older.